Met Life Investment Management, LLC Kala Pharmaceuticals, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021
SELL
$6.24 - $9.58 $118,154 - $181,397
-18,935 Closed
0 $0
Q4 2020

May 24, 2024
BUY
$6.28 - $8.79 $916 - $1,283
146 Added 0.78%
18,935 $128,000
Q4 2020

Jun 22, 2023
BUY
$6.28 - $8.79 $118,911 - $166,438
18,935 New
18,935 $128,000
Q4 2020

Mar 22, 2023
BUY
$6.28 - $8.79 $916 - $1,283
146 Added 0.78%
18,935 $128,000
Q4 2020

Feb 16, 2021
BUY
$6.28 - $8.79 $916 - $1,283
146 Added 0.78%
18,935 $128,000
Q3 2020

Jun 26, 2023
BUY
$7.5 - $11.11 $140,917 - $208,745
18,789 New
18,789 $140,000
Q2 2020

May 24, 2024
BUY
$8.33 - $13.79 $156,512 - $259,100
18,789 New
18,789 $197 Million
Q2 2020

Jun 26, 2023
BUY
$8.33 - $13.79 $156,512 - $259,100
18,789 New
18,789 $197,000
Q2 2020

Mar 22, 2023
BUY
$8.33 - $13.79 $54,769 - $90,669
6,575 Added 53.83%
18,789 $197,000
Q2 2020

Aug 14, 2020
BUY
$8.33 - $13.79 $54,769 - $90,669
6,575 Added 53.83%
18,789 $197,000
Q1 2020

Jul 12, 2023
BUY
$3.83 - $8.79 $46,779 - $107,361
12,214 New
12,214 $107,000
Q1 2020

Mar 22, 2023
BUY
$3.83 - $8.79 $46,779 - $107,361
12,214 New
12,214 $107,000
Q1 2020

May 15, 2020
BUY
$3.83 - $8.79 $46,779 - $107,361
12,214 New
12,214 $107,000
Q2 2018

Aug 15, 2018
SELL
$13.3 - $17.49 $99,896 - $131,367
-7,511 Closed
0 $0
Q1 2018

May 15, 2018
BUY
$12.26 - $18.98 $92,084 - $142,558
7,511 New
7,511 $119,000

Others Institutions Holding KALA

# of Institutions
1
Shares Held
1
Call Options Held
0
Put Options Held
0
View Full List

About Kala Pharmaceuticals, Inc.

KALA Quotes by TradingView
  • Ticker KALA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 1,464,160
  • Market Cap $8.67M
  • Description
  • Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...
More about KALA
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email